These treatment strategies primarily harness the endogenous cytotoxicity of CD8+ T cells to destroy cancer cells, this frequently leads to the development of drug resistance in the cancer cells, hence diminishing the treatment's effectiveness. This evidence concerns the gene CD8A and cancer.